|Systematic name||Methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate|
3,4-dichloromethylphenidate (also known by the incorrectly abbreviated name 3,4-ctmp) is a stimulant substance of the phenidate class. it is a structural analog of methylphenidate (ritalin). the two substances have similar pharmacological profiles but different subjective effects.
it is approximately seven times more potent than methylphenidate in animal studies, but likely has weaker reinforcing effects due to its slower onset of action. according to anecdotal reports, the active dose of 3,4-ctmp is approximately 10 times lower than the dose of methylphenidate to achieve a similar effect. 3,4-ctmp has a duration of 6 to 18 hours rather than the 4 to 6 hour duration found with methylphenidate.
3,4-ctmp has an extremely short history of human recreational use and has yet to be documented being sold on the streets. it is available for sale as grey market research chemical by online vendors.
due to its potent stimulant effects, habit-forming properties as well as an unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if using with this substance.
3,4-ctmp, or 3,4-dichloromethylphenidate, is a synthetic molecule of the substituted phenethylamine class. it contains a phenethylamine core featuring a phenyl ring bound to an amino -nh2 group through an ethyl chain. it is structurally similar to amphetamine, featuring a substitution at rα which is incorporated into a piperidine ring ending at the terminal amine of the phenethylamine chain. additionally, it contains a methyl acetate bound to r2 of its structure and is chlorinated at r3 and r4 of its phenyl ring.
3,4-ctmp is nearly identical in structure to methylphenidate; the difference is that it contains two chlorine atoms bonded to the phenyl group at the 3 and 4 positions.
3,4-ctmp acts as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. this allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects. 3,4-ctmp has also been identified as a relatively potent agonist of 5-ht2b serotonin receptors. this is concerning, as agonism of the 5-ht2b receptors results in a potentially serious effect called pulmonary hypertension, where the pulmonary artery that pumps blood from the heart to the lungs constricts. additionally, chronic stimulation of 5-ht2b receptors has been implicated in serious heart valve disease via fibrosis. other drugs with this effect, such as aminorex (a pharmaceutical weight loss drug that was pulled from the market), have resulted in a large number of long term heart injuries and fatalities across the world.
Johann BaptistV. –